Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term antagonists & inhibitors. Found 144 abstracts

no pagination
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9.   PMCID: PMC5857389
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74.   PMCID: Review
Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86.
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathog. 2018 Nov;14(11):e1007394.   PMCID: PMC6237423
Keohane CE, Steele AD, Fetzer C, Khowsathit J, Van Tyne D, Moynie L, Gilmore MS, Karanicolas J, Sieber SA, Wuest WM. Promysalin Elicits Species-Selective Inhibition of Pseudomonas aeruginosa by Targeting Succinate Dehydrogenase. J Am Chem Soc. 2018 Feb 07;140(5):1774-82.   PMCID: PMC5869686
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
de Oliveira JF, Lima TS, Vendramini-Costa DB, de Lacerda Pedrosa SC, Lafayette EA, da Silva RM, de Almeida SM, de Moura RO, Ruiz A, de Carvalho JE, de Lima M. Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay. European journal of medicinal chemistry. 2017 Aug 18;136:305-14.
Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017 Aug 15;77(16):4402-13.   PMCID: PMC5559306
Huang Q, He S, Tian Y, Gu Y, Chen P, Li C, Huang J, Liu Y, Yu H, Jin M, Hu S, Tong Q, Ma A, Jin J, Hexner E, Fung H, Reshef R, Zhang Y, Zhang Y. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood. 2017 May 18;129(20):2737-48.   PMCID: PMC5437825
Leclerc D, Pham DN, Levesque N, Truongcao M, Foulkes WD, Sapienza C, Rozen R. Oncogenic role of PDK4 in human colon cancer cells. Br J Cancer. 2017 Mar 28;116(7):930-6.   PMCID: PMC5379150
Liu B, Tang L, Zhang X, Ma J, Sehgal M, Cheng J, Zhang X, Zhou Y, Du Y, Kulp J, Guo JT, Chang J. A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists. Antiviral research. 2017 Nov;147:37-46.   PMCID: PMC5789800
Lu H, Liu S, Zhang G, Bin W, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 Oct 05;550(7674):133-6.   PMCID: PMC5891348
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2017 Oct 02;8(4):193-8.   PMCID: PMC5680705
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.   PMCID: Review
Cheng D, Zhao S, Tang H, Zhang D, Sun H, Yu F, Jiang W, Yue B, Wang J, Zhang M, Yu Y, Liu X, Sun X, Zhou Z, Qin X, Zhang X, Yan D, Wen Y, Peng Z. MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget. 2016 Jul 19;7(29):45199-213.   PMCID: PMC5216716
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Nov 10;34(32):3838-45.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term antagonists & inhibitors

antagonists & inhibitors drug therapy genetics Female pharmacology pathology Middle Aged Antineoplastic Agents chemistry adverse effects Male metabolism Tumor Cell Line drug effects Aged Monoclonal Antibodies-Humanized Adult therapeutic use Programmed Cell Death 1 Receptor administration & dosage Signal Transduction Protein Kinase Inhibitors 80 and over Aged Mice Disease-Free Survival B7-H1 Antigen Neoplasm Drug Resistance immunology Mutation Cell Proliferation Melanoma CTLA-4 Antigen Apoptosis Monoclonal Antibodies Kidney Neoplasms physiology Pyrimidines Neoplasms Neoplasm Metastasis Immunological Antineoplastic Agents methods Piperazines Immunotherapy therapy analysis Pyrazines Young Adult Kaplan-Meier Estimate prevention & control mortality Indoles Ovarian Neoplasms Tumor Biomarkers Renal Cell Carcinoma Child p21-Activated Kinases chemically induced Ipilimumab enzymology Inbred BALB C Mice Molecular Structure pembrolizumab Down-Regulation alpha Subunit Hypoxia-Inducible Factor 1 Therapy Colorectal Neoplasms p21 inactivated kinase agonists Tumor Microenvironment Pyridones MicroRNAs Innate immune Squamous Cell Carcinoma of Head and Neck Anti-Bacterial Agents Nucleotidyltransferases Minor Histocompatibility Antigens Diarrhea Receptor Protein-Tyrosine Kinases Lysine Hepatitis Immune-related adverse events biomarkers 3' Untranslated Regions Microbial Sensitivity Tests Innate Immunity Acetophenones Lethal Dose 50 Clear Cell Adenocarcinoma ovarian cancer Methylation Non-muscle-invasive Human Chromosomes-Pair 11 Angiogenesis Inhibitors Sunitinib Enzyme Activation Immunoenzyme Techniques Hypoxia-Inducible Factor 1 Intention to Treat Analysis DNA Methylation protein kinase Fatigue Species Specificity oncogene Vascular Endothelial Growth Factor A epidemiology Salicylamides Hypotension Interferon Inducers MAP Kinase Signaling System Small Interfering RNA Phenylurea Compounds Anticancer therapy Carcinogenesis Transitional Cell Carcinoma pd-1 Transcriptional Activation JNK Mitogen-Activated Protein Kinases Cell Cycle Checkpoints Thiosemicarbazones Preschool Child Local Neoplasm Recurrence Fallopian Tube Neoplasms Nivolumab Infant Host-Pathogen Interactions Intravenous Administration Type II DNA Topoisomerases pd-l1 chromosomal amplification Enhancer of Zeste Homolog 2 Protein Proportional Hazards Models Hematopoietic Stem Cell Transplantation Hematologic Neoplasms Smad4 Protein Piperidines beta Catenin colorectal cancer Topoisomerase inhibition Follow-Up Studies Human Herpesvirus 4 Histones DNA-Binding Proteins etiology biosynthesis Structure-Activity Relationship Mitogen-Activated Protein Kinases ctla-4 Preclinical Drug Evaluation Resorcinols Cultured Cells
Last updated on Friday, January 03, 2020